Acute toxicity of whole-pelvis IMRT in 87 patients with localized prostate cancer

Acta Oncologica

Volumn 47, Issue 2, 2008, Pages 301-310

  Sanguineti, Giuseppe ^a   Endres, Eugene J ^b   Parker, Brent C ^b   Bicquart, Celine ^a   Little, Michael ^a   Chen, George ^a   Berilgen, Jason ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE TOXICITY; ADULT; ARTICLE; CANCER RADIOTHERAPY; COLITIS; DIARRHEA; DYSURIA; GLEASON SCORE; HEMATURIA; HUMAN; INCONTINENCE; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROCTALGIA; PROCTITIS; PROSTATE CANCER; RADIATION DOSE; RADIATION ENTEROPATHY; RECTUM HEMORRHAGE; SCORING SYSTEM; SEMINAL VESICLE; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URINARY FREQUENCY; URINARY URGENCY; URINE RETENTION;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; PELVIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RISK FACTORS; URINARY INCONTINENCE;

EID: 38349158398     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701558849     Document Type: Article

References (32)

1. Roach M, 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003;21:1904-11.
2. Lawton CA, DeSilvio M, Roach M, et al. An update of the phase III trial comparing whole-pelvic (WP) to prostate only (PO) radiotherapy and neoadjuvant to adjuvant total androgen suppression (TAS): Updated analysis of RTOG 94-13. Int J Radiat Oncol Biol Phys 2005;63:S19 [abstract].
3. Roach M, 3rd, DeSilvio M, Valicenti R, et al. Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 2006;66:647-53.
4. Garg AK, Mai WY, McGary JE, et al. Radiation proctopathy in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 2006;66:1294-305.
5. Cavey ML, Bayouth JE, Colman M, et al. IMRT to treat the pelvic nodes while escalating the dose to the prostate. Strahlether Onkol 2005 (accepted for publication).
6. Luxton G, Hancock SL, Boyer AL. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2004;59:267-84.
7. Nutting CM, Convery DJ, Cosgrove VP, et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2000;48:649-56.
8. Wang-Chesebro A, Xia P, Coleman J, et al. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2006;66:654-62.
9. Sanguineti G, Cavey ML, Endres EJ, et al. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer? Int J Radiat Oncol Biol Phys 2006;64:151-60.
10. R.T.O.G. protocol 0521: A phase III protocol of androgen suppression (As) and 3DCRT/IMRT vs As and 3DCRT/ IMRT followed by chemotherapy with docetaxel and prednisone for localized, high-risk prostate cancer. www.rtog.org.
11. Ashman JB, Zelefsky MJ, Hunt MS, et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:765-71.
12. Jani AB, Su A, Milano MT. Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: Analysis of acute toxicity. Urology 2006;67:147-51.
13. Roach M, 3rd, Marquez C, Yuo HS, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994;28:33-7.
14. Fiorino C, Vavassori V, Sanguineti G, et al. Rectum contouring variability in patients treated for prostate cancer: Impact on rectum dose-volume histograms and normal tissue complication probability. Radiother Oncol 2002;63:249-55.
15. Sanguineti G, Culp L, Pena J, et al. Acute small bowel and colon toxicity after pelvic IMRT for prostate cancer. Eur J Cancer Suppl 2003;1:S268.
16. Sanguineti G, Culp LR, Endres EJ, et al. Are neck nodal volumes drawn on CT slices covered by standard three-field technique? Int J Radiat Oncol Biol Phys 2004;59:725-42.
17. Bentzen SM, Dorr W, Anscher MS, et al. Normal tissue effects: Reporting and analysis. Semin Radiat Oncol 2003;13:189-202.
18. Buyyounouski MK, Horwitz EM, Price RA, et al. Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. Int J Radiat Oncol Biol Phys 2004;58:743-9.
19. Liu L, Glicksman AS, Coachman N, et al. Low acute gastrointestinal and genitourinary toxicities in whole pelvic irradiation of prostate cancer. Int J Radiat Oncol Biol Phys 1997;38:65-71.
20. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111-6.
21. Vavassori V, Fiorino C, Rancati T, et al. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: Results of a prospective multicenter study. Int J Radiat Oncol Biol Phys 2007;67:1401-10.
22. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005;61:1019-34.
23. Gelblum DY, Potters L, Ashley R, et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999;45:59-67.
24. Lee WR, DeSilvio M, Lawton C, et al. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: Preliminary results of RTOG P-0019. Int J Radiat Oncol Biol Phys 2006;64:804-9.
25. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review. Radiother Oncol 2003;66:253-62.
26. De Meerleer G, Vakaet L, Meersschout S, et al. Intensity-modulated radiotherapy as primary treatment for prostate cancer: Acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 2004;60:777-87.
27. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
28. Trotti A. The evolution and application of toxicity criteria. Semin Radiat Oncol 2002;12:1-3.
29. Bos LJ, Damen EM, de Boer RW, et al. Reduction of rectal dose by integration of the boost in the large-field treatment plan for prostate irradiation. Int J Radiat Oncol Biol Phys 2002;52:254-65.
30. Williams SG, Taylor JMG, Liu N, et al. Estimation of the a/β ratio of prostate cancer using a multivariate analysis of the individual fraction size data of 3756 patients. Int J Radiat Oncol Biol Phys 2006;66:S10-1.
31. Boersma LJ, van den Brink M, Bruce AM, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998;41:83-92.
32. Sanguineti G, Cavey ML, Endres EJ, et al. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy? Strahlenther Onkol 2006;182:543-9.